Status:
COMPLETED
Efficacy and Safety of CONAN® Proctological Cream for Treatment of Haemorrhoidal Disease
Lead Sponsor:
Omikron Italia S.r.l.
Conditions:
Hemorrhoid Pain
Haemorrhoid Inflammation
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
Aim of the study is to assess the efficacy, safety and tolerability of CONAN® (Proctological Cream, Medical Device, Omikron Italia Srl) on most frequent symptoms in grade 1-2 of haemorrhoidal disease ...
Detailed Description
Background: To evaluate the role of CONAN® Proctological Cream containing escin, hesperidin and hyaluronic acid in topical treatment of haemorrhoidal disease and anal fissures and its potential effica...
Eligibility Criteria
Inclusion
- Aged between 18 and 70 years
- Hemorrhoidal pathology, anal fissures and anitis
- NRS score ≥ 3 for at least one of the symptoms (burning, itching, feeling of heaviness, foreign body)
Exclusion
- Known hypersensitivity to study products
- Proctitis
- Current therapy with other local treatments based on phlebotropes and/or anti-inflammatories
- Surgical treatments undergone less than a year after inclusion
- Pregnancy, breastfeeding
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05984641
Start Date
March 1 2022
End Date
September 30 2022
Last Update
April 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Policlinico Tor Vergata Foundation (PTV)
Rome, Italy, 00133